文献速递皮肤肿瘤

黑色素瘤类型对免疫检查点抑制剂治疗中皮肤免疫相关不良事件发生率及下游结局的影响

Influence of melanoma type on incidence and downstream implications of cutaneous immune-related adverse events in the setting of immune checkpoint inhibitor therapy.
PubMed 文献 · J Am Acad Dermatol · 2023-02-22

这项回顾性多机构队列研究纳入747例免疫检查点抑制剂(ICI)治疗的黑色素瘤患者,236例(31.6%)发生皮肤免疫相关不良事件(cirAE)。肢端黑色素瘤患者发生cirAE的可能性低于非肢端皮肤黑色素瘤(HR=0.41,P=.016);所有亚型中cirAE与死亡风险降低相关(HR=0.76,P=.042);肢端(HR=2.04,P=.005)、黏膜(HR=2.30,P<.001)和葡萄膜(HR=4.09,P<.001)原发黑色素瘤患者生存最差。

要点

  • 747例ICI治疗的黑色素瘤患者中,236例(31.6%)发生cirAE。
  • 肢端黑色素瘤患者发生cirAE的风险低于非肢端皮肤黑色素瘤患者(HR=0.41,P=.016)。
  • 所有黑色素瘤亚型中,cirAE与死亡风险降低相关(HR=0.76,P=.042)。

核心结论

  • 本研究首次证明不同黑色素瘤亚型间cirAE发生存在差异。
  • cirAE的出现与更好的生存相关。
  • cirAE发生率较低可能是免疫治疗反应的标志,这反映在肢端黑色素瘤与死亡风险的关联中。

研究设计与样本

  • 回顾性多机构队列研究。
  • 共纳入747例接受免疫检查点抑制剂(ICI)治疗的黑色素瘤患者。
  • 采用多变量时间序列回归评估黑色素瘤亚型、cirAE发生与生存之间的关系。

主要发现

  • 747例ICI治疗患者中,236例(31.6%)发生cirAE。
  • 肢端黑色素瘤患者发生cirAE的可能性低于非肢端皮肤黑色素瘤患者(HR=0.41,P=.016)。
  • 所有黑色素瘤亚型中,cirAE与死亡风险降低相关(HR=0.76,P=.042)。
  • 肢端原发黑色素瘤患者生存最差(HR=2.04,P=.005)。
  • 黏膜原发黑色素瘤患者生存最差(HR=2.30,P<.001);葡萄膜原发黑色素瘤患者生存最差(HR=4.09,P<.001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 回顾性队列研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Emerging evidence suggests that cutaneous immune-related adverse events (cirAEs) are associated with a survival benefit in the setting of advanced melanoma treated with immune checkpoint inhibitor (ICI) therapy. Previous studies have not examined the role of melanoma subtypes on cirAE development and downstream therapeutic outcomes. OBJECTIVE: Examine the impact of melanoma subtypes on cirAE onset and survival among ICI recipients. METHODS: Retrospective multi-institutional cohort study. Multivariate time-series regressions were utilized to assess relationships between melanoma subtype, cirAE development, and survival. RESULTS: Among 747 ICI recipients, 236 (31.6%) patients developed a cirAE. Patients with acral melanoma were less likely to develop a cirAE (hazard ratio [HR] = 0.41, P = .016) compared to patients with nonacral cutaneous melanoma. Across all melanoma subtypes, cirAEs were associated with reduced mortality (HR = 0.76, P = .042). Patients with acral (HR = 2.04, P = .005), mucosal (HR = 2.30, P < .001), and uveal (HR = 4.09, P < .001) primaries exhibited the worst survival. LIMITATIONS: Retrospective cohort study. CONCLUSION: This is the first study to demonstrate differences in cirAE development among melanoma subtypes. The presence of cirAEs was associated with better survival. Further, the lower incidence of cirAEs may be a marker of immunotherapy response, which is reflected in the association between acral melanoma and mortality.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Nguyen N, Wan G, Ugwu-Dike P, et al. Influence of melanoma type on incidence and downstream implications of cutaneous immune-related adverse events in the setting of immune checkpoint inhibitor therapy. J Am Acad Dermatol. 2023. PMID: 36828138. doi:10.1016/j.jaad.2023.02.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。